VivoSeq
Oncology

Advanced Malignant Solid Neoplasm

22

Pipeline Programs↗

8

Active Trials↗

13

Companies Involved↗

Advanced Malignant Solid Neoplasm is an emerging landscape with 22 programs across 13 companies. The most active players are RasCal Therapeutics, Inc., Chong Kun Dang Pharmaceutical, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

6/100

Mech. Concentration

6/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

RasCal Therapeutics, Inc.

1 program

Phase 1Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical

1 program

Phase 1Pfizer logo

Pfizer

3 programs

Phase 2AstraZeneca logo

AstraZeneca

2 programs

Phase 2Teva logo

Teva

2 programs

Phase 2Amgen logo

Amgen

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

19 of 23 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody313%Protein / enzyme14%

Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

8

clinical trials

Recruiting5 · 63%
Active, not recruiting3 · 38%

Clinical Trials

Trial Activity

8 trials

Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05327010·88 enrolled
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT05564377·2,900 enrolled
A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors
Recruiting·OOHSU Knight Cancer Institute·Preclinical·NCT06320405·38 enrolled
Empowerment Through Preparedness: Improving Advance Care Planning (ACP) in Adolescents and Young Adults (AYAs) With Advanced Solid Malignancies and High-Grade Brain Tumors
Recruiting·MMayo Clinic·Preclinical·NCT07174661·50 enrolled
A Phase Ia/Ib, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies
Recruiting·RRasCal Therapeutics, Inc.·Phase 1·NCT04678648·134 enrolled
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03213652·13 enrolled
A Combination Therapy for Cancer-Related Fatigue in Advanced Cancer Patients
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03583255·99 enrolled
A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT03212274·89 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)